Monoclonal antibodies treatment
Page 1 of 1 • Share
Monoclonal antibodies treatment
If you have recently tested positive for COVID-19 and have had symptoms for 10 days or less, talk to your health care provider to see if monoclonal antibody therapy is an option for you or find a treatment center near you. Some people may qualify for preventative treatment before showing symptoms. If you have been exposed to COVID-19, talk to your health care provider for more.
Your body naturally makes antibodies to fight infection. However, your body may not have antibodies designed to recognize a new virus like SARS-CoV-2, the virus that causes COVID-19. The Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) to allow the use of monoclonal antibody therapies for the treatment of mild to moderate COVID-19 in certain high-risk patients.
Monoclonal antibodies, or mAbs, are made in a laboratory to fight a particular infection—in this case, the virus that causes COVID-19—and are given to patients directly with an infusion or a shot. That’s why mAb treatment may help patients who are at high risk for severe symptoms or hospitalization.
Some early evidence suggests that mAb treatment can reduce the amount of the virus, or viral load, that causes COVID-19 in a person's body. Having a lower viral load means you may have milder symptoms, which decreases the likelihood hospitalization.
This treatment may help people who:
Have tested positive for COVID-19 and have symptoms for 10 days or less, and
Are at high risk of getting more serious symptoms.
https://covid19.ncdhhs.gov/about-covid-19/treatment/monoclonal-antibodies-treatment-covid-19?mc_cid=0bf073ea56&mc_eid=80b2eddb5c
Your body naturally makes antibodies to fight infection. However, your body may not have antibodies designed to recognize a new virus like SARS-CoV-2, the virus that causes COVID-19. The Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) to allow the use of monoclonal antibody therapies for the treatment of mild to moderate COVID-19 in certain high-risk patients.
Monoclonal antibodies, or mAbs, are made in a laboratory to fight a particular infection—in this case, the virus that causes COVID-19—and are given to patients directly with an infusion or a shot. That’s why mAb treatment may help patients who are at high risk for severe symptoms or hospitalization.
Some early evidence suggests that mAb treatment can reduce the amount of the virus, or viral load, that causes COVID-19 in a person's body. Having a lower viral load means you may have milder symptoms, which decreases the likelihood hospitalization.
This treatment may help people who:
Have tested positive for COVID-19 and have symptoms for 10 days or less, and
Are at high risk of getting more serious symptoms.
https://covid19.ncdhhs.gov/about-covid-19/treatment/monoclonal-antibodies-treatment-covid-19?mc_cid=0bf073ea56&mc_eid=80b2eddb5c
TuTu
Similar topics
» New coronavirus subvariants escape antibodies from vaccination
» Silent Treatment
» WHO said: Malaria drug will be one of the treatment options
» FDA clears first Covid antibody treatment
» UK regulator approves ‘first of its kind’ Covid antibody treatment
» Silent Treatment
» WHO said: Malaria drug will be one of the treatment options
» FDA clears first Covid antibody treatment
» UK regulator approves ‘first of its kind’ Covid antibody treatment
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum